Introduction {#Sec1}
============

Protein translation is essential for all forms of life. Within this process, aminoacyl transfer RNA (tRNA) synthetases (ARSs) play an important role. This highly conserved ubiquitously expressed class of enzymes is responsible for correct coupling of amino acids to their cognate tRNAs,^[@CR1]--[@CR3]^ which base pair with messenger RNA (mRNA) triplets.^[@CR4]^ This ensures incorporation of correct amino acids in the growing polypeptide chain during protein synthesis. Each proteinogenic amino acid is coupled to its corresponding tRNA by a specific ARS,^[@CR1]^ as reflected in the ARS nomenclature (for example IARS for isoleucine-tRNA synthetase; LARS for leucine-tRNA synthetase). Because protein translation takes place in both the cytosol and mitochondria, mammalian cells possess cytosolic and mitochondrial ARSs. Mitochondrial ARSs are encoded by separate nuclear genes (nomenclature: *ARS2*), with the exception of *KARS*, *GARS*, and *QARS*, which encode both the cytosolic and mitochondrial ARSs.^[@CR1]^

Over the past 15 years, an increasing proportion of *ARS* genes has been associated with human disease. In the first description, a heterozygous missense pathogenic variation in *GARS* was found to cause Charcot--Marie--Tooth disease type 2D, a peripheral axonal neuropathy.^[@CR5]^ Subsequently, other dominant pathogenic variations in *GARS*,^[@CR6]--[@CR16]^ *YARS*,^[@CR17],[@CR18]^ *AARS*,^[@CR19]--[@CR24]^ *HARS*,^[@CR25]^ *KARS*,^[@CR26]^ and *MARS*^[@CR27]^ have been associated with peripheral axonal neuropathies. In the past 10 years, pathogenic variations in mitochondrial *ARS*s (*DARS2*, *RARS2*, *EARS2*, *MARS2*, *FARS2*, *YARS2*, *SARS2*, *AARS2*, and *HARS2)*^[@CR28]^ have emerged as a cause of human disease. The clinical presentation of these mitochondrial diseases was reported to depend on the affected ARS, with encephalopathy as the most common manifestation. Only in the past 5 years have homozygous and compound heterozygous pathogenic variations been identified in cytosolic *LARS*,^[@CR29],[@CR30]^ *AARS*,^[@CR31],[@CR32]^ *MARS*,^[@CR33]--[@CR35]^ *IARS*,^[@CR36],[@CR37]^ *YARS*,^[@CR38]^ *VARS*,^[@CR39]^ *RARS*,^[@CR40]^ *DARS*,^[@CR41]^ *HARS*,^[@CR42]^ *SARS*,^[@CR43]^ and in the combined cytosolic and mitochondrial *QARS*,^[@CR44]--[@CR47]^ *GARS*,^[@CR48]--[@CR50]^ and *KARS*^[@CR26],[@CR51]--[@CR54]^ genes. The resulting autosomal recessive diseases show considerable clinical variability and involve numerous organs without apparent logic.

With the increasing number of diagnosed patients, insight in the pathophysiological mechanism is crucial for optimal clinical care. To this end, we reviewed literature for patients with autosomal recessive ARS deficiencies. We additionally deep phenotyped five patients with novel compound heterozygous pathogenic variations in *IARS*, *LARS*, *KARS*, and *QARS* and illustrate the common themes in disease presentation.

Materials and methods {#Sec2}
=====================

A literature search was performed up to July 2017 in PubMed and Embase (search terms tRNA synthetase deficiency, ARS deficiency, (individual) *ARS* pathogenic variations) and through references in retrieved publications. Clinical details and laboratory results were retrieved from the manuscripts and supplemental material. The search was supplemented with all patients seen in our hospital with recessive ARS deficiencies diagnosed through exome sequencing. Exomes were enriched using Agilent SureSelect XT Human All Exon kit V5 and sequenced on a HiSeq sequencing system (Illumina). Reads were aligned to hg19 using Burrows--Wheeler Aligner. Variants were called using Genome Analysis Toolkit variant caller and annotated, filtered, and prioritized using the Bench NGS Lab platform (Agilent-Cartagenia, Leuven, Belgium) and/or an in-house designed "variant interface" and manual curation. Patients were evaluated according to our clinical practice and all laboratory analyses were performed in ISO 9001/ISO15189 accredited diagnostic laboratories. Clinical and laboratory findings were categorized. Findings reported in \>30% (≥4/13) of individual ARS deficiencies were considered common among ARS deficiencies.

Results {#Sec3}
=======

We identified 107 children with homozygous or compound heterozygous pathogenic variations in 10 different cytosolic and 3 combined cytosolic and mitochondrial *ARS* genes (Fig. [1](#Fig1){ref-type="fig"}, Table S[1](#MOESM2){ref-type="media"}). All reported ARS deficiencies were associated with affected central nervous system (CNS) and/or senses (hearing/sight), most with failure to thrive (10/13) and many with feeding problems (6/13), dysmaturity (5/13), and liver symptoms (4/13). Signs of mitochondrial dysfunction and facial dysmorphisms were common (6/13 and 4/13, respectively, including all three combined cytosolic and mitochondrial ARSs) and various endocrine abnormalities (4/13). Symptoms were most severe in the first year of life (4/13) and during infections and included acute liver failure and status epilepticus and/or encephalopathy (4/13).Fig. 1Clinical symptoms of patients with autosomal recessive ARS deficiencies reported in literature (left part) and supplemented with P1--5 (right part).Gray squares represent symptoms reported for 1 patient, black squares symptoms reported for \>1 patient. Categories of symptoms occurring in \>30% of the individual ARS deficiencies are marked in orange for patients reported in literature and in red after addition of P1--5. MRI magnetic resonance imaging, LVH left ventricular hypertrophy

We additionally identified five patients with pathogenic variations in *ARS* genes (nomenclature according to Human Genome Variation Society \[HGVS\] guidelines):P1, female, died at age 4 months, compound heterozygous pathogenic variations in *IARS* (NM_002161.5): c.1305G\>C p.(Trp435Cys) and c.3377dup p.(Asn1126fs)P2, male, now age 5 years, compound heterozygous pathogenic variations in *IARS* (NM_002161.5): c.1305G\>C p.(Trp435Cys) and c.3377dup p.(Asn1126fs). The parents originate from the same region as P1, which may suggest a founder effect for their common pathogenic variationP3, female, now age 5.5 years, compound heterozygous pathogenic variations in *LARS* (NM_020117.10): c.3420del p.(Ile1141fs) and c.1283C\>T p.(Pro428Leu)P4, male, died at age 4 years, compound heterozygous pathogenic variations in *KARS* (NM_001130089.1): c1732_1744delGGCATTGATCGAG, p.(Gly578SerfsX20) and c.683C\>T p.(Pro228Leu)P5, male, now age 4 years, compound heterozygous pathogenic variations in *QARS* (NM_005051.2): c.2084+2_2084+3del p.(?) and c.793C\>T p.(Arg25Cys)

Similar to the patients reported in literature, we observed CNS symptoms, growth/feeding problems, and liver disease (Fig. [1](#Fig1){ref-type="fig"}, Table S[1](#MOESM2){ref-type="media"}).

CNS symptoms {#Sec4}
------------

P1, P2, and P5 were born and remained microcephalic (\<--2SDS, Fig. [2](#Fig2){ref-type="fig"}). Head circumference at birth of P3--4 are unknown, but subsequent measurements were normal. CNS was most seriously affected in P4--5 with combined mitochondrial and cytosolic ARS deficiencies. Both patients had severe global developmental delays. P4 had an estimated developmental age of 4 months at age 4 years, involving eye contact, intentional laugh, recognition of parents, hypotonia, bipyramidal syndrome combined with extrapyramidal movements, but no rolling nor independent sitting. P5 had an estimated developmental age of 9 months at age 3.5 years, involving independent sitting and standing with support, but no crawling, language development, or interest in toys. Both patients had severe epilepsy. P4 had a permanent electroencephalogram (EEG) pattern of a (non)convulsive status epilepticus and from the age of 6 months jerky movements of the extremities, head, and/or eyes, somewhat improving with levetiracetam and clonazepam. P5 had a refractory epileptic encephalopathy despite ketogenic diet, deteriorating with vaccination/infections. In addition, P4 had severe perceptive hearing deficit, treated with cochlear implants and P5 severe occipital visual disturbance, with random eye movements and almost absent eye fixation or following.Fig. 2Growth curves of weight, length, and head circumference of P1--5.Arrows indicate hospitalization due to feeding problems requiring nasogastric tube feeding (P1--4). Striped bars represent periods of feeding by percutaneous endoscopic gastrostomy (P2, P3, P5) or nasogastric tube (P4). Notice that the ranges of the *x*-axes are not synchronized between patients due to age differences

Symptoms were milder in P1--3. Due to young age and hospitalization, development in P1 was difficult to judge. She was hypotonic, alert, made good eye contact, and passed her hearing test. P2--3 showed evidence of delayed global development (P2: global hypotonia, developmental quotients for global development, motoric skills, and verbal capacities ranging from 49 to 75 at age 3.5 years; P3: motor functioning p16, verbal IQ 81, performal IQ 70 at 5.5 years). P1--2 showed no evidence of epilepsy. P3 was hospitalized in her second and third year of life for three proven and one suspected status epilepticus, all triggered by infections. Electroencephalogram showed a focal left temporo-occipital lesion. Lamotrigine was started and no signs of epilepsy were noted after the age of 4 years.

Brain imaging of P3--5 showed distinct abnormalities (Fig. [3a](#Fig3){ref-type="fig"}). In P3, brain MRI showed periventricular white matter abnormalities (at age 13 months and 4.5 years), and focal cerebellar atrophy, without other neurodegenerative abnormalities or abnormalities of the thalami and basal ganglia. Magnetic resonance spectroscopy (MRS) showed elevated lactate peaks in white and gray matter. In P4, brain MRI at age 11 months showed hyperintense abnormalities in the substantia nigra. In P5, brain MRI was relatively normal at age 3 months, but displayed delayed white matter myelination, gradual loss of frontal periventricular white matter, and a relatively thin corpus callosum at age 1 year. At autopsy, microscopic evaluation of the brain of P1 (age 4 months) showed sparse white matter with decreased occipital myelination of U fibers. Neuronal damage, presumably toxic, was seen in the basal ganglia and thalamus and minor recent hypoxic/ischemic damage in cerebellar neurons.Fig. 3Radiologic and histologic findings.(**a**) Brain magnetic resonance image (MRI) scans of P3, P4, and P5. T2-weighted axial and T1-weighted coronal MRI in P3 at age 4.5 years show focal atrophy of the cerebellar cortex. T2-weighted MRI in P4 at age 11 months shows abnormalities in the substantia nigra. T1-weighted MRI in P5 at age 1 year shows delayed myelination with a relatively thin corpus callosum. (**b**) Histology shows severe cholestasis and steatosis in liver tissue (P1) in H&E staining (pseudorosette formation around bile plugs (brown). (**c**) Chest X-rays of P1--5. Interstitial abnormalities are visible in P1--P4. (**d**) Thoracic computed tomography (CT) scan in P2 at age 3 months shows extensive bilateral peribronchial consolidations, bronchus dilation, and subpleural ground glass consolidation with a remarkable dorso-basal distribution; at age 5 years it shows diffuse ground glass abnormalities, cystic lesions in a paraseptal--subpleural--bronchovascular distribution, and some thickening of interlobular septae. Thoracic CT scan in P3 at age 5 years shows thickening of interlobular septae in the upper and lower thorax. (**e**) Histology shows severe pulmonary alveolar proteinosis in lung tissue (P1 and P2) by staining for pankeratin marker CKAE1/3: (**a**: highlights the lining of the alveoli with reactive type 2 pneumocytes, **b**: H&E staining; **b**: P1 and P2 alveoli are filled with a dense, eosinophilic, amorphous, protein-lipid precipitate; P2 shows granular material in multivesicular bodies and absent formation of lamellar bodies in type 2 pneumocytes, and **c**: electron microscopy; **c**: alveoli contain laminated annular structures \[lamellar bodies\]). (**f**) Ultrasound of the kidneys in P4 shows a hyperechogenic cortex of the kidneys. The global intensity of the kidney cortex versus medulla and liver is too intense

Intrauterine growth restriction, feeding problems, and failure to thrive {#Sec5}
------------------------------------------------------------------------

Intrauterine growth restriction was noted at 20 weeks of pregnancy in P1 and 3. P1--3 were born severely dysmature (P1: 1770 g; P2: 2250 g; P3: 1495 g, Fig. [2](#Fig2){ref-type="fig"}), P4 p2.3--5 (2800 g) and P5 P20--50 (3125 g). There were no signs of placental insufficiency or infections. In P1--4, the neonatal period was characterized by feeding problems and grossly insufficient growth, requiring hospitalization and nasogastric/duodenal tube feeding (P1: age \<1 week, P2: 2 months, P3: 13 months, P4: 13 months), in P3 prompted by fasting intolerance (4.5--10 h). Percutaneous endoscopic gastrostomy was performed in P2, P3, and P5. Extensive analyses including gastrointestinal passage studies and esophagogastroduodenoscopy showed no anatomic, histologic abnormalities, nor malabsorption. With enteral feeding, growth normalized in P2, 3, and 5, but remained deficient in P4.

Liver disease {#Sec6}
-------------

P1--3 had markedly elevated liver enzymes (Fig. [4](#Fig4){ref-type="fig"}) in the first year of life, normalizing with age in P2 and to a lesser extent in P3. There were no signs of known (metabolic) liver diseases. During infections, liver enzymes rose dramatically in these patients, accompanied by transient (P3) and refractory (P1) ascites in the context of progressive liver failure. Liver ultrasound imaging showed normal homogeneous aspect at age 1 month and progressive enlargement from age 2 months onwards in P1; a slightly enlarged, diffusely hyperechogenic liver and left lobe hypertrophy, with normalization of echogenicity from age 2.5 years onwards in P2; and an enlarged liver with multiple hypoechogenic masses at 13 months, confirmed with MRI abdomen and persistent at age 5.5 years, with then also echogenic nodules in the pancreas in P3. Liver biopsy showed micro- and macrovesicular steatosis in P1 and combined steatosis and cirrhosis in P3. Liver steatosis, cholestasis, and extensive fibrosis were present at autopsy in P1 (Fig. [3b](#Fig3){ref-type="fig"}). Conversely, P4 only showed elevated liver enzymes in the final stage of his disease and P5 only during two episodes of antiepileptic drug introduction.Fig. 4Laboratory findings of P1--5.Notice that the ranges of the *x*-axes are not synchronized between patients due to age differences. ALT alanine transaminase, AST aspartate transaminase, CRP C-reactive protein, gamma-GT, gamma-glutamyltransferase

Additional common clinical symptoms {#Sec17}
-----------------------------------

### Hypoalbuminemia {#Sec7}

Blood albumin concentrations were severely decreased P1--4 in their first year of age and increased temporarily upon albumin infusions in P1--2 (Fig. [4](#Fig4){ref-type="fig"}). There were no signs of intestinal or renal protein loss. Protein electrophoresis showed proportional protein deficiency, suggestive of a general protein synthesis defect. In P2--4, hypoalbuminemia resolved spontaneously with age (P2: 11 months, P3: 18 months, and P4: 30 months, followed by severe hypoalbuminemia in his last episode of life). Albumin was only determined after age 17 months in P5 and was normal.

### Anemia {#Sec79}

Anemia was present in all five patients (Fig. [4](#Fig4){ref-type="fig"}) and hematocrit paralleled hemoglobin levels. Mean corpuscular volume was elevated in P1, P2, and P5 (up to 90--100, reference range: 73--87 fl), but low to normal in P3--4 (62--83 fl), while mean corpuscular hemoglobin was normal (1.75--2.25 fmol, P1 and P5), decreased to 1.3 fmol (P2) or low (1.19--1.65 fmol; P3--4). Mean corpuscular hemoglobin concentration was normal in all patients. Reticulocytes were low (13 × 10^9^/L) in the first 3 months in P1 and rose to 180 × 10^9^/L at 3.5 months, varied between 34 and 127 × 10^9^/L in P2 and were normal in P4--5 (25--120 × 10^9^/L). The immature reticulocyte fraction was increased (to 0.5; normal range 0.09--0.31) and erythroblasts were present (to maximally 0.42 × 10^9^/L) in P1, P2, and P4. Morphology varied between normal and mild and inconsistent abnormalities. There were no signs of blood loss or hemolysis (no association with elevated bilirubin or lactate dehydrogenase (LDH) levels). Bone marrow aspiration in P2 showed a markedly elevated ratio of granulopoiesis to erythropoiesis (5:1). Taken together, these results imply aberrant erythropoiesis in the first year(s) of life in our patients. P1--2 were treated with repetitive erythrocyte transfusions; P3 with a transfusion followed by iron therapy until age 6 months. At age 11 months, she was still anemic while ferritin concentration was high (305 ug/L, reference range: 25--250 µg/L); iron was started in P4 at age 14 months, compensating low ferritin concentrations (5--10 µg/l) and normalizing hemoglobin. With age, anemia gradually resolved.

### Inflammation {#Sec81}

In the first 6 months of life, P1 and P2 showed an inflammatory reaction with severe leukocytosis with predominantly neutrophils, varying thrombocytosis (P1: normal to 600 × 10^9^/L; P2: 400--1400 × 10^9^/L; reference range: 150--450 × 10^9^/L), elevated C-reactive protein (CRP) and ferritin concentrations (P1: 680--1050 µg/L, reference range: 20--150 µg/L) (Fig. [4](#Fig4){ref-type="fig"}). Treatment with corticosteroids temporarily normalized CRP and leukocytes in P1. After age 1 year, leukocytes and thrombocytes gradually normalized in P2. However, CRP remains elevated (\>15 mg/L) up to his current age of 4.5 years. Bone marrow aspiration and blood smear showed myeloid and lymphoid dysplasia as seen in aberrant stimulation, without evidence of malignancies. P4 also displayed inflammatory reactions in the first month of life and during infections, with leukocytosis, thrombocytosis (550--600 × 10^9^/L), and elevated CRP, and complete normalization thereafter. P3 and P5 had normal CRP and leukocyte concentrations and adequate inflammatory response during infections.

### Pulmonary alveolar proteinosis {#Sec83}

Respiratory symptoms were most prominent in P2, with respiratory distress at age 2 months requiring high-flow nasal oxygen administration and two days of invasive ventilation. Thoracic chest X-ray and high-resolution CT (HR-CT) scan (Fig. [3c,d](#Fig3){ref-type="fig"}) showed extensive bilateral interstitial pulmonary abnormalities. Lung histology revealed pulmonary alveolar proteinosis (PAP) (Fig. [3e](#Fig3){ref-type="fig"}). He is still dependent on oxygen administration and recently developed cystic abnormalities (Fig. [3d](#Fig3){ref-type="fig"}). P1 required invasive ventilation during respiratory syncytial virus infection and could not be weaned from the ventilator nor oxygen. At autopsy, severe PAP was evident (Fig. [3e](#Fig3){ref-type="fig"}). P3 has been hospitalized once for pneumonia. She is easily fatigued, without overt respiratory symptoms. She has digital clubbing like her father. Aware of PAP in P1--2, chest X-rays were performed (Fig. [3c](#Fig3){ref-type="fig"}). Interstitial abnormalities, compatible with PAP, were noted and confirmed by thoracic HR-CT scan at age 5 years (Fig. [3d](#Fig3){ref-type="fig"}). P4 presented with fever, dyspnea, and respiratory insufficiency requiring ventilatory support at age 4 years. Chest X-ray showed signs of infection without clear interstitial pulmonary abnormalities (Fig. [3c](#Fig3){ref-type="fig"}). Further investigations were not conducted. P5 has no history of respiratory symptoms. Thoracic chest X-ray was performed once (Fig. [3c](#Fig3){ref-type="fig"}) upon presentation with fever and tachypnea. Symptoms resolved after antibiotic treatment.

### Metabolic abnormalities {#Sec85}

Analysis of urine from P1--2 showed increased excretion of galactose (maximal 1219 mmol/mol creatinine and 2534 mmol/mol creatinine, respectively, reference range: \<838 mmol/mol creatinine) and galactitol (maximal 1082 mmol/mol creatinine and 378 mmol/mol creatinine, respectively, reference range: \<107 mmol/mol creatinine), which normalized after lactose free feeding in P1 and spontaneously in P2. Enzyme activities involved in galactose breakdown and neonatal screening results for galactosemia were reviewed and normal in P1.

P1--2 and sporadically P4--5 displayed generalized aminoaciduria, which normalized with age in P2. Renal ultrasound in P4 showed bilateral increased renal cortex echogenicity (Fig. [3f](#Fig3){ref-type="fig"}), but no other signs of renal pathology.

Other metabolic abnormalities were only seen in individual patients, including for P1 increased cholesterol intermediates (cholestanol-7 and 8-dehydrocholesterol), putatively resulting from cholestasis or hypoalbuminemia and abnormal isoelectric focusing of serum transferrins, possibly secondary to liver failure or inflammation; for P2 increased urinary excretion of ethylmalonic acid (maximally 55 mmol/mol creatinine at age 5 months, reference range: \<20 mmol/mol creatinine) and bile acids, and elevated chitotriosidase blood concentration (62.5 µmol/hour/L, reference range: \<37.1 µmol/hour/L) at age 3 months, putatively reflecting the inflammatory state; for P5 elevated blood and urine methylmalonic acid concentrations (maximally 3.11µmol/L; reference range: 0.12--0.25 µmol/L; and 102 mmol/mol creatinine; reference range: 0--20 mmol/mol creatinine, respectively) at age 3 months; there was no evidence of nutritional deficiencies with normal vitamin B12 and homocysteine concentrations. All abnormalities normalized with age.

Metabolic investigations were performed in P3 at age 13 months upon presentation with hypoglycemia, abnormal liver enzymes, and status epilepticus. She displayed elevated cerebrospinal fluid (CSF) lactate concentrations, but normal lactate/pyruvate ratio and alanine concentrations. Urinary lactate and pyruvate excretion were elevated, but organic acid excretion was normal. Oral glucose tolerance test showed a slight rise in lactate and low--normal ketone body production. Muscle biopsy revealed decreased substrate oxidation velocity and ATP + CrP production (10.9 nmol/h.mUCS, reference range: 15.4--30.2 nmol/h.mUCS), but normal enzyme activities of all respiratory chain enzymes, complex V, pyruvate dehydrogenase complex (PDHc) PDHc, and citrate synthetase. There were no signs of mitochondrial depletion syndromes or *POLG*, *DGUOK*, and *MPV17* pathogenic variations. Glycogen storage diseases and lysosomal diseases (Niemann--Pick, lysosomal acid lipase deficiency \[LALD\]) were ruled out by enzyme assays and tyrosinemia and aberrant sugar or polyol metabolism by urinary analyses.

As might be expected, P4 showed evidence of mitochondrial dysfunction with elevated lactate levels in CSF (5.3 mmol/L, reference range: 1.1--2.1 mmol/L) and plasma (3.5--10 mmol/L, reference range: 0--2.2 mmol/L). Values rose after glucose challenge, with concomitantly increased urinary excretion of citric acid cycle intermediates. Lactate, pyruvate, alanine, and citric acid cycle intermediates dramatically increased in the final stage of disease. Muscle biopsy showed decreased substrate oxidation velocity and ATP + CrP production (7.4 nmol/h.mUCS, reference values 15.4--30.2 nmol/h.mUCS), but normal enzyme activities of the respiratory chain enzymes, complex V, and citrate synthetase. Pathogenic variation analysis of *POLG* revealed no pathogenic variations. P5 showed normal lactate concentrations in blood and CSF, except during the period of epileptic encephalopathy (blood lactate concentration: 5.2 mmol/L).

Discussion {#Sec13}
==========

Autosomal recessive ARS deficiencies represent a rapidly growing group of severe inherited diseases, involving multiple organs, currently without curative options. The rising number of recognized patients allows us to search for a potential common clinical phenotype, which might improve clinical recognition, insight into the disease mechanism, and clinical care. To this end, we compared clinical phenotypes of 112 patients with pathogenic variations in 10 cytosolic and 3 combined cytosolic and mitochondrial *ARS* genes, including all previously described patients with autosomal recessive ARS deficiencies we could identify in literature, supplemented with five new patients.

All ARS deficiencies were associated with CNS symptoms, including deficient hearing and/or sight, and most with failure to thrive, feeding, and gastrointestinal problems. Liver disease, chubby cheeks/facial dysmorphisms, various endocrine abnormalities, and mitochondrial dysfunction were reported for \>30% of the different ARS deficiencies (Fig. [1](#Fig1){ref-type="fig"}, orange) as was the pattern of severe symptoms in the first months of life and during infections. Identification of common clinical features from literature might underestimate true symptom overlap. Sometimes, not all clinical features were described, especially when studies were performed in specific cohorts of patients (HARS)^[@CR42]^ or for specific clinical features (intellectual disability \[SARS\],^[@CR43]^ leukoencephalopathy and leg spasticity \[DARS\],^[@CR41]^ hypomyelination \[RARS\],^[@CR40]^ neurogenetic disease \[VARS\],^[@CR39]^ nonsyndromic hearing impairment \[KARS\]).^[@CR51]^ We emphasize the importance of deep phenotyping in novel genetic diseases with five supplementary patients and encourage reporting all symptoms, also when not suspected as a core clinical feature. This allowed us to also classify lung disease, hypoalbuminemia, bone marrow, and kidney abnormalities as common (Fig. [1](#Fig1){ref-type="fig"}, red). Moreover, some symptoms might only be noted after specific diagnostic evaluation, as illustrated for restrictive lung disease in our IARS (P1) and LARS (P3) deficient patients.

Our findings suggest a strikingly common clinical phenotype for LARS, MARS, and IARS and to a slighter extent YARS and AARS deficiencies. Potentially, all symptoms reported for cytosolic ARS deficiencies represent the spectrum of a common clinical phenotype. Conversely, some features might be characteristic for specific ARS deficiencies. Nine cytosolic ARSs (IARS, LARS, MARS, QARS, KARS, RARS, DARS, and EPRS) form a multisynthetase complex (MSC). The major role ascribed to the MSC is to improve translational efficiency. Putatively, pathogenic variations in this subset of ARSs result in common symptoms based on deficient MSC function. Alternatively, symptoms might relate to specific amino acids (individually or to groups like branched chain amino acids), based on abundancy in specific proteins or to common (non)canonical amino acid or ARS functions. Combined cytosolic and mitochondrial ARS deficiencies obviously represent a specific subgroup, with mitochondrial dysfunction reflected in laboratory findings, muscle biopsy, and affected organs with high oxidative metabolism (brain, heart). Similarly, sensorineural hearing impairment is frequently seen in other mitochondrial ARS deficiencies, including LARS2, HARS2, RARS2,^[@CR55]^ and IARS2.^[@CR54]^ However, anemia and hypoalbuminemia in our KARS deficient patient and hepatosplenomegaly during infancy in QARS deficiencies^[@CR46]^ might imply involvement of the cytosolic ARS deficiency. Conversely, although the multiorgan phenotype might suggest a mitochondriopathy, we did not find evidence for mitochondrial dysfunction caused directly by the cytosolic ARS deficiency.

The overlap in clinical phenotype between pathogenic variations in different *ARS*s suggests a general disease mechanism. Pathogenic variations causing recessive ARS deficiencies generally reside in catalytic or anticodon binding domains of *ARS* genes (Fig. [5a](#Fig5){ref-type="fig"}). The most straightforward hypothesis therefore confers that aminoacylation is insufficient to meet translational demand in specific organs, especially during high demands in the first year of life and infections (Fig. [5b](#Fig5){ref-type="fig"}). Concurrently, aminoacylation activity was decreased in mutant alleles from patients with AARS,^[@CR31],[@CR32]^ MARS,^[@CR33],[@CR34]^ IARS,^[@CR36]^ HARS,^[@CR42]^ SARS,^[@CR43]^ QARS,^[@CR44],[@CR46]^ and KARS^[@CR26]^ deficiencies, but never to an enzyme activity of \<8% from normal (Table S[2](#MOESM3){ref-type="media"}). The fact that heterozygous parents of patients are unaffected suggests that on the other hand there is some excess capacity in ARS activity.Fig. 5Putative disease mechanism for autosomal recessive ARS deficiencies.(**a**) Overview of the pathogenic variations found in autosomal recessive ARS deficiencies, concentrated in the domains associated with the canonical function in protein translation. The novel pathogenic variations described for P1--P5 are underlined. (**b**) Schematic representation of the putative disease mechanism: insufficient aminoacylation to meet translational demand in specific organs or periods. tRNA transfer RNA

Intrauterine growth restriction and failure to thrive seem closely related to a disease mechanism involving reduced aminoacylation activity, translational slowdown or inefficiency, and consequential decreased proliferation. Indeed, growth was diminished in complementation assays in yeast with mutant *AARS*,^[@CR31]^ *IARS*,^[@CR36]^ *MARS*,^[@CR34]^ *GARS*,^[@CR50]^ and *KARS* ^[@CR53]^ alleles. Similarly, hypoalbuminemia would well align with this disease mechanism, because albumin synthesis is very sensitive to amino acid depletion, particularly for leucine, isoleucine, and tryptophane.^[@CR56]^ Moreover, organs most prominently affected in recessive ARS deficiencies are the organs with highest amino acid incorporation rates: liver (2.4%/hr), lung (1.0%/hr), brain (0.6%/hr), and muscle (0.4--0.7%/hr)^[@CR57]^ or high proliferation rates (intestine). This also concurs with the prominence of symptoms during perinatal growth and infections, periods of high translational demand. It remains unclear why other highly proliferative organs like the skin are not affected, except in one patient with IARS deficiency and skin hyperelasticity^[@CR37]^ and two sibs with QARS deficiency with a dry rough skin.^[@CR46]^

PAP was previously thought to be a specific feature of MARS deficiency.^[@CR33]--[@CR35]^ We show that other recessive ARS deficiencies (IARS and LARS) can also cause PAP. Furthermore, our IARS deficient patient developed cystic abnormalities with time, as reported in YARS deficient patients.^[@CR38]^ PAP results from the accumulation of lipoproteins in pulmonary alveoli, leading to restrictive lung disease and respiratory failure.^[@CR58]^ Most commonly involved in the pathogenesis is defective granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor activation, either through GM-CSF autoantibodies^[@CR59]^ or rare pathogenic variations in GM-CSF receptor genes.^[@CR60]^ This leads to deficient alveolar macrophage maturation, which is essential for macrophages to clear and recycle surfactant. Interestingly, among patients with autoimmune antisynthetase syndromes, antibodies against ARSs strongly predict interstitial lung disease.^[@CR61]^ In addition, PAP is also a clinical characteristic of lysinuric protein intolerance (LPI), a rare inherited metabolic disease^[@CR62]^ caused by a defective cationic amino acid transporter in the kidney, small bowel, lung, spleen, monocytes, and macrophages, resulting in leakage of cationic amino acids (arginine, ornithine, and lysine). Thus a shortage of amino acids, antibodies against ARSs, and genetic ARS deficiencies can all result in PAP, putatively through reduced aminoacylation and deficient translation to ensure adequate surfactant composition or homeostasis. Interestingly, LPI patients show considerable overlap in clinical phenotype with recessive ARS deficiencies, involving neurological impairment, failure to thrive, hepatosplenomegaly, PAP, renal tubulopathy, and hemophagocytic lymophohistiocytosis.^[@CR62]^ The fact that both reduced amino acid concentrations and ARS deficiencies can result in common clinical symptoms concurs with insufficient aminoacylation for efficient translation as disease mechanism.

If reduced aminoacylation leads to symptoms in patients with recessive ARS deficiencies and if patients have some residual enzyme activity, then supplementation of the corresponding amino acid or high protein intake might improve symptoms. This is in sharp contrast with the traditional management of replacing protein by glucose in patients with metabolic hepatic disease, but aligns with the previous advice to patients with *LARS* pathogenic variations^[@CR29],[@CR30]^ to supply a minimum of 2.5 g/kg of whole protein either enterally or parenterally while unwell. This is supported by the restoration of growth upon increased intake with tube feeding in P1--3 (Fig. [2](#Fig2){ref-type="fig"}). Similarly, the clinical phenotype in a patient with MARS deficiency improved after starting parenteral nutrition^[@CR33]^ and MARS aminoacylation activity and proliferation in yeast with mutant *MARS* alleles improved upon methionine supplementation.^[@CR34]^

In conclusion, through deep phenotyping of five patients with novel compound heterozygous *IARS*, *LARS*, *KARS*, and *QARS* pathogenic variations, we were able to add lung disease, hypoalbuminemia, anemia, and renal tubulopathy to the common phenotype we derived from literature for cytosolic ARS deficiencies, involving CNS abnormalities, growth restriction, liver symptoms, and facial dysmorphisms. This highlights the importance of deep phenotyping in patients with novel rare genetic diseases. Identification of a common clinical phenotype implies that recessive pathogenic variations in newly identified cytosolic ARSs may result in similar clinical symptoms, which might improve disease recognition and guide diagnostic work-up. Insufficient aminoacylation activity to meet high translational demand as common disease mechanism would also guide therapeutic care. As some residual enzyme activity seems essential for life, adequate supply of protein/amino acids is crucial, especially during periods of increased translational demand, including the first year of life and infections.
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